RUA Life Sciences Sees Wider 2022 Pretax Loss on Increased Investments
marketwatch.com
news
2022-05-27 06:50:00

By Michael Susin RUA Life Sciences PLC said on Friday that it expects a widened pretax loss for fiscal 2022 as it has increased research-and-development activities and infrastructure investment. The AIM-listed medical-devices group expects to book a pretax loss for the year ended March 31 of 2.4 million pounds ($3 million) compared with GBP1.6 million the previous year. Revenue is expected to be at GBP1.6 million compared with GBP1.5 million. The company said expenses on research and development are GBP346,000 higher than previous year, bringing to an expected total of GBP887,000.
